Hycamtin achieves promising results in study of patients with leukemia.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002166:Camptothecin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D004334:Drug Administration Schedule; D004791:Enzyme Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006801:Humans; D015477:Leukemia, Myelomonocytic, Chronic / Q000188:drug therapy*; D009190:Myelodysplastic Syndromes / Q000188:drug therapy*; D010051:Ovarian Neoplasms / Q000188:drug therapy; D012074:Remission Induction; D019772:Topotecan
D004791:Enzyme Inhibitors; D019772:Topotecan; D002166:Camptothecin